Cargando…
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887512/ https://www.ncbi.nlm.nih.gov/pubmed/33614518 http://dx.doi.org/10.3389/fonc.2021.650149 |
| _version_ | 1783651999957385216 |
|---|---|
| author | Sam, Johannes Colombetti, Sara Fauti, Tanja Roller, Andreas Biehl, Marlene Fahrni, Linda Nicolini, Valeria Perro, Mario Nayak, Tapan Bommer, Esther Schoenle, Anne Karagianni, Maria Le Clech, Marine Steinhoff, Nathalie Klein, Christian Umaña, Pablo Bacac, Marina |
| author_facet | Sam, Johannes Colombetti, Sara Fauti, Tanja Roller, Andreas Biehl, Marlene Fahrni, Linda Nicolini, Valeria Perro, Mario Nayak, Tapan Bommer, Esther Schoenle, Anne Karagianni, Maria Le Clech, Marine Steinhoff, Nathalie Klein, Christian Umaña, Pablo Bacac, Marina |
| author_sort | Sam, Johannes |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7887512 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78875122021-02-18 Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity Sam, Johannes Colombetti, Sara Fauti, Tanja Roller, Andreas Biehl, Marlene Fahrni, Linda Nicolini, Valeria Perro, Mario Nayak, Tapan Bommer, Esther Schoenle, Anne Karagianni, Maria Le Clech, Marine Steinhoff, Nathalie Klein, Christian Umaña, Pablo Bacac, Marina Front Oncol Oncology Frontiers Media S.A. 2021-02-03 /pmc/articles/PMC7887512/ /pubmed/33614518 http://dx.doi.org/10.3389/fonc.2021.650149 Text en Copyright © 2021 Sam, Colombetti, Fauti, Roller, Biehl, Fahrni, Nicolini, Perro, Nayak, Bommer, Schoenle, Karagianni, Le Clech, Steinhoff, Klein, Umaña and Bacac http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Sam, Johannes Colombetti, Sara Fauti, Tanja Roller, Andreas Biehl, Marlene Fahrni, Linda Nicolini, Valeria Perro, Mario Nayak, Tapan Bommer, Esther Schoenle, Anne Karagianni, Maria Le Clech, Marine Steinhoff, Nathalie Klein, Christian Umaña, Pablo Bacac, Marina Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title | Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title_full | Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title_fullStr | Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title_full_unstemmed | Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title_short | Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity |
| title_sort | corrigendum: combination of t-cell bispecific antibodies with pd-l1 checkpoint inhibition elicits superior anti-tumor activity |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887512/ https://www.ncbi.nlm.nih.gov/pubmed/33614518 http://dx.doi.org/10.3389/fonc.2021.650149 |
| work_keys_str_mv | AT samjohannes corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT colombettisara corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT fautitanja corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT rollerandreas corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT biehlmarlene corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT fahrnilinda corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT nicolinivaleria corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT perromario corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT nayaktapan corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT bommeresther corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT schoenleanne corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT karagiannimaria corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT leclechmarine corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT steinhoffnathalie corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT kleinchristian corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT umanapablo corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity AT bacacmarina corrigendumcombinationoftcellbispecificantibodieswithpdl1checkpointinhibitionelicitssuperiorantitumoractivity |